Form 4: Lexeo Therapeutics Director Acquires 15,000 Shares

Paula H Cholmondeley, a director at Lexeo Therapeutics, acquired 15,000 shares of common stock at a price of $6.9901 per share on November 25, 2024.

Summary

• Paula H Cholmondeley, a director of Lexeo Therapeutics, purchased 15,000 shares of the company's common stock.
• The transaction occurred on November 25, 2024.
• The purchase price was $6.9901 per share.
• Following the transaction, Ms. Cholmondeley directly owns 30,627 shares of Lexeo Therapeutics.
• 15,627 of these shares are subject to vesting, with 1/48th vesting monthly starting December 1, 2021, contingent on continuous service.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a routine transaction by a director. The purchase could be seen as a positive sign, but it's not a major event.

Positives

• The director's purchase of shares could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for directors and officers who may receive stock as part of their compensation or choose to invest in the company.
• The vesting schedule is a common practice to incentivize long-term commitment from employees and directors.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Lexeo Therapeutics, insider trading, share acquisition, director, common stock, LXEO, vesting